ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value
This article was originally published in The Pink Sheet Daily
The British health care company has decided not to spin out a minority stake in its fast-growing HIV joint venture, in part because of feedback from investors against the idea.
You may also be interested in...
GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.
Deal brings GSK/Pfizer HIV-focused affiliate two novel mechanisms, one of which could be used in combination with Tivicay and another that addresses a different stage of the virus' lifecycle than any HIV drug now approved.
"Stand-out" sales of Tivicay and Triumeq validate GSK's decision earlier this year to hang on to its stake in ViiV Healthcare.